U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C42H53NO15.ClH
Molecular Weight 848.329
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACLARUBICIN HYDROCHLORIDE

SMILES

Cl.[H][C@@]1(CCC(=O)[C@H](C)O1)O[C@H]2[C@@H](O)C[C@]([H])(O[C@@H]3[C@H](C)O[C@]([H])(C[C@@H]3N(C)C)O[C@H]4C[C@](O)(CC)[C@H](C(=O)OC)C5=CC6=C(C(=O)C7=C(O)C=CC=C7C6=O)C(O)=C45)O[C@H]2C

InChI

InChIKey=KUSMIBXCRZTVML-PCCPLWKKSA-N
InChI=1S/C42H53NO15.ClH/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29;/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3;1H/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+;/m0./s1

HIDE SMILES / InChI

Molecular Formula C42H53NO15
Molecular Weight 811.8679
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 13 / 13
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Torsade de pointes ventricular tachycardia in a patient with acute myelocytic leukemia].
1991 Sep
Oxidative stress involvement in chemically induced differentiation of K562 cells.
2000 Jan 1
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week
Route of Administration: Intravenous
In Vitro Use Guide
aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:16:26 UTC 2023
Edited
by admin
on Fri Dec 15 15:16:26 UTC 2023
Record UNII
501948RI66
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACLARUBICIN HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
ACLARUBICIN HYDROCHLORIDE [MART.]
Common Name English
Aclarubicin hydrochloride [WHO-DD]
Common Name English
ACLARUBICIN HYDROCHLORIDE [JAN]
Common Name English
ACLACINOMYCIN A HYDROCHLORIDE
Common Name English
ACLARUBICIN HCL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C987
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
Code System Code Type Description
EVMPD
SUB00285MIG
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
ChEMBL
CHEMBL502620
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
CAS
75443-99-1
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID4046658
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
PUBCHEM
153751
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
NCI_THESAURUS
C95830
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
ECHA (EC/EINECS)
278-209-3
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
FDA UNII
501948RI66
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
SMS_ID
100000078812
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
DRUG BANK
DBSALT001935
Created by admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY